schliessen

Filtern

 

Bibliotheken

Anti-HER2 functionalized graphene oxide as survivin-siRNA delivery carrier inhibits breast carcinoma growth in vitro and in vivo

Background: The success of gene therapy is mostly dependent on the development of gene carrier. Graphene oxide (GO) possesses excellent aqueous solubility and biocompatibility, which is important for its biochemical and medical applications. Our previous work proved that GO can deliver siRNA into ce... Full description

Journal Title: Drug Design Development and Therapy, 2018, Vol.12, pp.2841-2855
Main Author: Wang, Xiaoli
Other Authors: Sun, Qi , Cui, Chunying , Li, Jing , Wang, Yifan
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1177-8881 ; DOI: 10.2147/DDDT.S169430
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest2226298131
title: Anti-HER2 functionalized graphene oxide as survivin-siRNA delivery carrier inhibits breast carcinoma growth in vitro and in vivo
format: Article
creator:
  • Wang, Xiaoli
  • Sun, Qi
  • Cui, Chunying
  • Li, Jing
  • Wang, Yifan
subjects:
  • Beijing China
  • United States–Us
  • Germany
  • China
  • Japan
  • Cytotoxicity
  • Antibodies
  • Nanoparticles
  • Cytotoxicity
  • Gene Therapy
  • Survival
  • Nanomaterials
  • Polymerase Chain Reaction
  • Biomedical Materials
  • Peptides
  • In Vivo Methods and Tests
  • Apoptosis
  • Toxicity
  • Kinases
ispartof: Drug Design, Development and Therapy, 2018, Vol.12, pp.2841-2855
description: Background: The success of gene therapy is mostly dependent on the development of gene carrier. Graphene oxide (GO) possesses excellent aqueous solubility and biocompatibility, which is important for its biochemical and medical applications. Our previous work proved that GO can deliver siRNA into cells efficiently and downregulate the expression of desired protein. Methods: In this study, a novel delivery carrier, GO-R8/anti-HER2 (GRH), was developed by conjugating octaarginine (R8) and anti-HER2 antibody with GO as a tumor active-targeting vector for survivin-siRNA delivery. Results: GRH/survivin-siRNA formed nanoglobes of 195±10 nm in diameter. Real-time polymerase chain reaction analysis revealed that survivin messenger RNA expression showed a 42.4%±2.69% knockdown. The expression of survivin protein was downregulated to 50.86%±2.94% in enzyme-linked immunosorbent assay. In MTT tests, GRH exhibited no testable cytotoxicity. In vivo, GRH/survivin-siRNA showed gene silencing and inhibition...
language: eng
source:
identifier: E-ISSN: 1177-8881 ; DOI: 10.2147/DDDT.S169430
fulltext: fulltext_linktorsrc
issn:
  • 11778881
  • 1177-8881
url: Link


@attributes
ID1604107195
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid2226298131
sourceidproquest
recordidTN_proquest2226298131
sourcesystemPC
pqid2226298131
galeid576062285
display
typearticle
titleAnti-HER2 functionalized graphene oxide as survivin-siRNA delivery carrier inhibits breast carcinoma growth in vitro and in vivo
creatorWang, Xiaoli ; Sun, Qi ; Cui, Chunying ; Li, Jing ; Wang, Yifan
ispartofDrug Design, Development and Therapy, 2018, Vol.12, pp.2841-2855
identifierE-ISSN: 1177-8881 ; DOI: 10.2147/DDDT.S169430
subjectBeijing China ; United States–Us ; Germany ; China ; Japan ; Cytotoxicity ; Antibodies ; Nanoparticles ; Cytotoxicity ; Gene Therapy ; Survival ; Nanomaterials ; Polymerase Chain Reaction ; Biomedical Materials ; Peptides ; In Vivo Methods and Tests ; Apoptosis ; Toxicity ; Kinases
descriptionBackground: The success of gene therapy is mostly dependent on the development of gene carrier. Graphene oxide (GO) possesses excellent aqueous solubility and biocompatibility, which is important for its biochemical and medical applications. Our previous work proved that GO can deliver siRNA into cells efficiently and downregulate the expression of desired protein. Methods: In this study, a novel delivery carrier, GO-R8/anti-HER2 (GRH), was developed by conjugating octaarginine (R8) and anti-HER2 antibody with GO as a tumor active-targeting vector for survivin-siRNA delivery. Results: GRH/survivin-siRNA formed nanoglobes of 195±10 nm in diameter. Real-time polymerase chain reaction analysis revealed that survivin messenger RNA expression showed a 42.4%±2.69% knockdown. The expression of survivin protein was downregulated to 50.86%±2.94% in enzyme-linked immunosorbent assay. In MTT tests, GRH exhibited no testable cytotoxicity. In vivo, GRH/survivin-siRNA showed gene silencing and inhibition...
languageeng
source
version8
oafree_for_read
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
linktorsrc$$Uhttp://search.proquest.com/docview/2226298131/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Wang, Xiaoli
1Sun, Qi
2Cui, Chunying
3Li, Jing
4Wang, Yifan
titleAnti-HER2 functionalized graphene oxide as survivin-siRNA delivery carrier inhibits breast carcinoma growth in vitro and in vivo
descriptionBackground: The success of gene therapy is mostly dependent on the development of gene carrier. Graphene oxide (GO) possesses excellent aqueous solubility and biocompatibility, which is important for its biochemical and medical applications. Our previous work proved that GO can deliver siRNA into cells efficiently and downregulate the expression of desired protein. Methods: In this study, a novel delivery carrier, GO-R8/anti-HER2 (GRH), was developed by conjugating octaarginine (R8) and anti-HER2 antibody with GO as a tumor active-targeting vector for survivin-siRNA delivery. Results: GRH/survivin-siRNA formed nanoglobes of 195±10 nm in diameter. Real-time polymerase chain reaction analysis revealed that survivin messenger RNA expression showed a 42.4%±2.69% knockdown. The expression of survivin protein was downregulated to 50.86%±2.94% in enzyme-linked immunosorbent assay. In MTT tests, GRH exhibited no testable cytotoxicity. In vivo, GRH/survivin-siRNA showed gene silencing and inhibition...
subject
0Beijing China
1United States–Us
2Germany
3China
4Japan
5Cytotoxicity
6Antibodies
7Nanoparticles
8Gene Therapy
9Survival
10Nanomaterials
11Polymerase Chain Reaction
12Biomedical Materials
13Peptides
14In Vivo Methods and Tests
15Apoptosis
16Toxicity
17Kinases
18graphene oxide
19GO
20survivin-siRNA
21anti-HER2 antibody
22small interfering RNA
23gene delivery
24nanocarrier
general
0English
1Taylor & Francis Ltd.
210.2147/DDDT.S169430
3Nursing & Allied Health Database (Alumni edition)
4Nursing & Allied Health Database
5Publicly Available Content Database
6Engineering Research Database
7Technology Research Database
8ProQuest Nursing & Allied Health Source
9ProQuest Research Library
10ProQuest Biological Science Collection
11ProQuest Central
12ProQuest Engineering Collection
13ProQuest Environmental Science Collection
14ProQuest Hospital Collection
15ProQuest Natural Science Collection
16ProQuest Technology Collection
17Research Library (Alumni edition)
18Hospital Premium Collection (Alumni edition)
19ProQuest SciTech Collection
20Agricultural & Environmental Science Database
21Biological Science Database
22Materials Science & Engineering Database
23Natural Science Collection
24ProQuest Central (new)
25ProQuest Central K-12
26ProQuest Central Korea
27Research Library Prep
28SciTech Premium Collection
29Technology Collection
30Health Research Premium Collection
31Health Research Premium Collection (Alumni edition)
32ProQuest Central Essentials
33ProQuest One Academic
34Environmental Science Index (ProQuest)
35Biological Science Index (ProQuest)
36Engineering Index (ProQuest)
37Environmental Science Collection (ProQuest)
38Engineering Collection (ProQuest)
sourceidproquest
recordidproquest2226298131
issn
011778881
11177-8881
rsrctypearticle
creationdate2018
addtitleDrug Design, Development and Therapy
searchscope
01006759
11006763
21006993
31007107
41007443
51007898
61007899
71007902
81008004
91008005
101008008
111008875
121008886
131009127
141009240
1510000004
1610000005
1710000013
1810000015
1910000020
2010000022
2110000025
2210000034
2310000038
2410000039
2510000041
2610000043
2710000047
2810000050
2910000053
3010000064
3110000117
3210000118
3310000119
3410000120
3510000164
3610000198
3710000209
3810000217
3910000234
4010000238
4110000250
4210000253
4310000255
4410000256
4510000257
4610000258
4710000259
4810000260
4910000265
5010000270
5110000271
5210000281
5310000348
5410000349
5510000350
5610000353
5710000354
5810000356
5910000360
60proquest
scope
01006759
11006763
21006993
31007107
41007443
51007898
61007899
71007902
81008004
91008005
101008008
111008875
121008886
131009127
141009240
1510000004
1610000005
1710000013
1810000015
1910000020
2010000022
2110000025
2210000034
2310000038
2410000039
2510000041
2610000043
2710000047
2810000050
2910000053
3010000064
3110000117
3210000118
3310000119
3410000120
3510000164
3610000198
3710000209
3810000217
3910000234
4010000238
4110000250
4210000253
4310000255
4410000256
4510000257
4610000258
4710000259
4810000260
4910000265
5010000270
5110000271
5210000281
5310000348
5410000349
5510000350
5610000353
5710000354
5810000356
5910000360
60proquest
lsr43
01006759true
11006763true
21006993true
31007107true
41007443false
51007898true
61007899true
71007902true
81008004true
91008005true
101008008true
111008875true
121008886true
131009127true
141009240true
1510000004false
1610000005false
1710000013false
1810000015false
1910000020true
2010000022false
2110000025true
2210000034true
2310000038false
2410000039true
2510000041false
2610000043false
2710000047true
2810000050false
2910000053false
3010000064true
3110000117true
3210000118true
3310000119true
3410000120false
3510000164true
3610000198false
3710000209false
3810000217false
3910000234false
4010000238false
4110000250false
4210000253false
4310000255true
4410000256true
4510000257true
4610000258true
4710000259true
4810000260false
4910000265false
5010000270true
5110000271true
5210000281true
5310000348true
5410000349false
5510000350false
5610000353false
5710000354false
5810000356false
5910000360true
startdate20180101
enddate20180101
citationpf 2841 pt 2855 vol 12
lsr30VSR-Enriched:[galeid, pqid]
sort
titleAnti-HER2 functionalized graphene oxide as survivin-siRNA delivery carrier inhibits breast carcinoma growth in vitro and in vivo
authorWang, Xiaoli ; Sun, Qi ; Cui, Chunying ; Li, Jing ; Wang, Yifan
creationdate20180101
lso0120180101
facets
frbrgroupid6895162989969557907
frbrtype5
newrecords20190519
languageeng
creationdate2018
topic
0Beijing China
1United States–Us
2Germany
3China
4Japan
5Cytotoxicity
6Antibodies
7Nanoparticles
8Gene Therapy
9Survival
10Nanomaterials
11Polymerase Chain Reaction
12Biomedical Materials
13Peptides
14In Vivo Methods and Tests
15Apoptosis
16Toxicity
17Kinases
collection
0Nursing & Allied Health Database (Alumni edition)
1Nursing & Allied Health Database
2Publicly Available Content Database
3Engineering Research Database
4Technology Research Database
5ProQuest Nursing & Allied Health Source
6ProQuest Research Library
7ProQuest Biological Science Collection
8ProQuest Central
9ProQuest Engineering Collection
10ProQuest Environmental Science Collection
11ProQuest Hospital Collection
12ProQuest Natural Science Collection
13ProQuest Technology Collection
14Research Library (Alumni edition)
15Hospital Premium Collection (Alumni edition)
16ProQuest SciTech Collection
17Agricultural & Environmental Science Database
18Biological Science Database
19Materials Science & Engineering Database
20Natural Science Collection
21ProQuest Central (new)
22ProQuest Central K-12
23ProQuest Central Korea
24Research Library Prep
25SciTech Premium Collection
26Technology Collection
27Health Research Premium Collection
28Health Research Premium Collection (Alumni edition)
29ProQuest Central Essentials
30ProQuest One Academic
31Environmental Science Index (ProQuest)
32Biological Science Index (ProQuest)
33Engineering Index (ProQuest)
34Environmental Science Collection (ProQuest)
35Engineering Collection (ProQuest)
prefilterarticles
rsrctypearticles
creatorcontrib
0Wang, Xiaoli
1Sun, Qi
2Cui, Chunying
3Li, Jing
4Wang, Yifan
jtitleDrug Design, Development and Therapy
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext_linktorsrc
addata
aulast
0Wang
1Sun
2Cui
3Li
aufirst
0Xiaoli
1Qi
2Chunying
3Jing
4Yifan
au
0Wang, Xiaoli
1Sun, Qi
2Cui, Chunying
3Li, Jing
4Wang, Yifan
atitleAnti-HER2 functionalized graphene oxide as survivin-siRNA delivery carrier inhibits breast carcinoma growth in vitro and in vivo
jtitleDrug Design, Development and Therapy
risdate20180101
volume12
spage2841
epage2855
pages2841-2855
eissn1177-8881
formatjournal
genrearticle
ristypeJOUR
abstractBackground: The success of gene therapy is mostly dependent on the development of gene carrier. Graphene oxide (GO) possesses excellent aqueous solubility and biocompatibility, which is important for its biochemical and medical applications. Our previous work proved that GO can deliver siRNA into cells efficiently and downregulate the expression of desired protein. Methods: In this study, a novel delivery carrier, GO-R8/anti-HER2 (GRH), was developed by conjugating octaarginine (R8) and anti-HER2 antibody with GO as a tumor active-targeting vector for survivin-siRNA delivery. Results: GRH/survivin-siRNA formed nanoglobes of 195±10 nm in diameter. Real-time polymerase chain reaction analysis revealed that survivin messenger RNA expression showed a 42.4%±2.69% knockdown. The expression of survivin protein was downregulated to 50.86%±2.94% in enzyme-linked immunosorbent assay. In MTT tests, GRH exhibited no testable cytotoxicity. In vivo, GRH/survivin-siRNA showed gene silencing and inhibition...
copMacclesfield
pubTaylor & Francis Ltd.
doi10.2147/DDDT.S169430
urlhttp://search.proquest.com/docview/2226298131/
oafree_for_read
date2018-01-01